Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma.

DNA methylation HCC PBMCs immune response

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 15 10 2019
accepted: 15 04 2020
entrez: 23 6 2020
pubmed: 23 6 2020
medline: 23 6 2020
Statut: ppublish

Résumé

Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) is the most common type of liver cancer in China. Thermal ablation is one of the main strategies for HCC treatment. However, few studies have investigated the properties of the immune response following thermal ablation thus far. In the present study, five subjects with HBV-associated HCC were recruited from The Beijing Youan Hospital. Peripheral blood mononuclear cells (PBMCs) were collected at three time points: Prior to thermal ablation (PR), 1-3 days post-ablation (P1) and 5-7 days post-ablation (P7). An Illumina 850K methylation microarray was employed to determine the DNA methylation profile of each sample. Data were analyzed using different methylation probes with the Bioconductor package in R. Following annotation of different methylation CG sites (CGs), the associated genes were subjected to an Ingenuity Pathway Analysis. A total of 3,000 significantly different CGs (adjusted P<0.05; |log(fold-change)|>0.5) were identified within the PR, P1 and P7 time points. Of these, 744 (24.8%) sites increased between the PR and P1 time points but gradually decreased at the P7 time point. The remaining 2,256 (75.2%) sites decreased between the PR and P1 time points gradually increased at the P7 time point. Following gene annotation of different CGs on the promoter, signaling pathways analysis demonstrated that 'p70S6K signaling', 'CXCR4 signaling', 'dendritic cell maturation', 'production of nitric oxide and reactive oxygen species in macrophages' pathways were activated at the P7 time point. The present study suggested that PBMC DNA methylation had changed soon after thermal ablation for subjects with HBV-associated HCC, and systemic immune responses were activated, particularly at the P7 time point.

Identifiants

pubmed: 32565992
doi: 10.3892/ol.2020.11636
pii: OL-0-0-11636
pmc: PMC7285841
doi:

Types de publication

Journal Article

Langues

eng

Pagination

677-684

Informations de copyright

Copyright: © Zhao et al.

Références

Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Int J Oncol. 2016 Aug;49(2):589-602
pubmed: 27221337
J Transl Med. 2013 Oct 29;11:273
pubmed: 24168056
Mediators Inflamm. 2015;2015:801685
pubmed: 26504362
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5503-12
pubmed: 26392541
Bull World Health Organ. 2019 Mar 1;97(3):230-238
pubmed: 30992636
Clin Epigenetics. 2018 Jan 18;10:8
pubmed: 29375724
F1000Res. 2016 Jun 08;5:1281
pubmed: 27347385
Radiology. 2009 Apr;251(1):1-2
pubmed: 19332838
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Nat Mater. 2017 Nov;16(11):1155-1161
pubmed: 29035356
Carcinogenesis. 2008 Oct;29(10):1901-10
pubmed: 18632756
Arthritis Rheum. 2003 Aug;48(8):2173-7
pubmed: 12905470
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Cell. 2017 Jun 29;170(1):142-157.e19
pubmed: 28648661
Theranostics. 2017 Aug 23;7(15):3732-3744
pubmed: 29109772
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Cell Mol Life Sci. 2002 Feb;59(2):241-57
pubmed: 11915942
J Int Med Res. 2019 Aug;47(8):3818-3830
pubmed: 31187666
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Virol. 2016 Sep 12;90(19):8934-46
pubmed: 27466420
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
Front Immunol. 2018 Dec 21;9:3018
pubmed: 30622535
Nat Immunol. 2008 Apr;9(4):339-42
pubmed: 18349809
Medicine (Baltimore). 2016 May;95(20):e3754
pubmed: 27196501
J Cancer. 2017 Oct 17;8(18):3742-3754
pubmed: 29151962
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Medicine (Baltimore). 2018 Oct;97(42):e12607
pubmed: 30334945
Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):173-81
pubmed: 22484804
J Hepatol. 2006 Dec;45(6):868-78
pubmed: 17046096
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Oncoimmunology. 2013 Nov 1;2(11):e26468
pubmed: 24498546
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
Korean J Radiol. 2018 Jul-Aug;19(4):613-622
pubmed: 29962868
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
Int J Hyperthermia. 2015;31(7):749-57
pubmed: 26365503
Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):416-422
pubmed: 30262419
J Hepatol. 2019 Apr;70(4):817
pubmed: 30739718
Ann Surg. 2006 Mar;243(3):321-8
pubmed: 16495695
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
Cancer Res. 2006 Jan 15;66(2):1139-46
pubmed: 16424051
Sci Rep. 2019 Mar 1;9(1):3260
pubmed: 30824840
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nature. 2017 Dec 21;552(7685):404-409
pubmed: 29236683

Auteurs

Yanan Zhao (Y)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.
Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Kang Li (K)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Jianping Sun (J)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Ning He (N)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Peng Zhao (P)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Chaoran Zang (C)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.
Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Xiaozhen Yang (X)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Caixia Hu (C)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Jiang Long (J)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Honghai Zhang (H)

Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Qi Wang (Q)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.
Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Yan Zhao (Y)

Clinical Detection Center, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Yonghong Zhang (Y)

Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.
Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, P.R. China.

Classifications MeSH